Tagged with NORD

Novo Nordisk The global COO of the multinational at the forefront of the fight against diabetes explains why the Algerian market is so strategically important and how the ‘made in Algeria’ brand would have real potential at the regional level if only the government would remove impediments to export. As COO of Novo…

diabetes Christine Marie D. Rosal, Country Manager of Novo Nordisk Pharmaceuticals (Philippines) gives a startling image of the current state of diabetes in the Philippines, the major reasons behind the soaring rates of diabetes and what the government along with companies such as Novo Nordisk can do to prevent a worsening…

Medicines Country Manager of Norpharma, Denmark, discusses how the company has been able to remain a market competitor while maintaining satisfactory payer prices. Since Norpharma’s founding in 1192, what are some of its key areas and products? We work in a number of strategic areas; pain management is where our heritage…

Sweden Anders Blanck of Lif Sweden discusses the Swedish healthcare system, why it’s contributing to the plunging profit margins in the pharma market, and the Swedish government’s heavy emphasis on cost-effectiveness.   Technically we have 21 different healthcare systems in our country, and they all have their own political bodies, run…

Dialysis The general manager of Baxter in the Nordic region discusses the concept of home care, and how brand new technologies currently being tested in Sweden should mean that soon, dialysis treatment will shift from the hospital to the home around the world. Could you please give us a brief introduction…

Generics Janssen has historically had a very strong focus on emerging markets. In today’s world, where growth for the pharmaceutical industry overwhelmingly comes from emerging markets, where do we find the Nordics?  What is the relevance of the Nordics for the country’s global footprint?  Jansen has preserved the cluster model. We…

Bavarian Nordic   If there is one thing that successful Danish companies have in common with one another, it is the clear recognition of abundant opportunities outside the motherland. “Danish companies’ strengths lie in their ability to build on what they have inherited from Denmark but to also look outward and be…

Denmark “The Nordic region—the ‘quiet North’ as it could have been called—counterbalances the turbulence in Southern Europe,” says Zinta Krumins, managing director Nordics, Boehringer Ingelheim, when asked about the relevance of the Nordics to the company. “The Nordics is a very stable region, with small but reasonable growth prospects, very good…

Nordic Drugs Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as a 100% owned subsidiary of Ferring in January 1995. Several years later, in 1998, we were divested out from Ferring. Today we are owned…

diabetes Carlos Manuel González Parra discusses the progress Novo Nordisk has made as a newcomer to the Colombian market and its hopes and intentions for the future. One of the main focuses is in manoeuvring Novo Nordisk Colombia into a position where they will be a key player in the diabetes…

Gilead Nordics As the blockbuster sales model fades, the rush is on for a new formula for growth, termed  ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable with high margins from protected pricing, more patient-friendly than patent-centric and with revenues coming from a deep reservoir of unmet medical need. How well…

Baltic You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see for AstraZeneca in pushing this development forward? AstraZeneca has a significant R&D presence in Sweden. We currently have more than 2,300 researchers at our…